Investor Alert

New York Markets Close in:

Ensysce Biosciences Inc.



Market open

 --Real time quotes

Jan 31, 2023, 12:53 p.m.





-0.02 -2.11%


Volume 586,565

Real time quotes


Previous close

$ 0.71

$ 0.70


-0.02 -2.11%

Day low

Day high




52 week low

52 week high




D. Lynn Kirkpatrick

D. Lynn Kirkpatrick founded Phusis Therapeutics, Inc. and ProlX Pharmaceuticals Corp. Presently, Dr. Kirkpatrick occupies the position of President, Chief Executive Officer & Director at Ensysce Biosciences, Inc.

In her past career she occupied the position of President & Chief Executive Officer for ProlX Pharmaceuticals Corp., President, Chief Executive Officer & Director at Ensysce Biosciences, Inc., Chief Scientific Officer for Biomira, Inc., Chief Scientific Officer of Cascadian Therapeutics LLC and Professor at the University of Regina.

Dr. Kirkpatrick received an undergraduate degree and a doctorate from the University of Saskatchewan.


Date Shares Transaction Value
05/26/2022 27,000   Acquisition at $0.53 per share. 14,310
05/25/2022 70,000   Acquisition at $0.49 per share. 34,300
06/30/2021 284,851   Award at $0 per share. 0

Officers and Executives

Dr. D. Lynn Kirkpatrick
President, Chief Executive Officer & Director
Dr. Jeffrey Millard
Chief Operating Officer
Mr. David Humphrey
Chief Financial Officer, Secretary & Treasurer
Dr. William K. Schmidt
Chief Medical Officer & SVP-Clinical Development
Mr. Geoffrey Birkett
Chief Commercial Officer
Mr. David Tanzer
Vice President-Strategic Development
Mr. Richard Wright
Chief Business Officer
Dr. Linda Pestano
Chief Development Officer
Dr. Bob G. Gower
Mr. Andrew K. Benton
Independent Director
Mr. William H. C. Chang
Independent Director
Dr. Adam S. Levin
Independent Director
Mr. Steven Robert Martin
Independent Director
Dr. Curtis Rosebraugh
Independent Director
Ms. Lee M. Rauch
Independent Director
Link to MarketWatch's Slice.